NAS:ATRA (USA) Also trade in: Germany UK

Atara Biotherapeutics Inc

$ 18.09 -0.22 (-1.2%)
Volume: 570,837 Avg Vol (1m): 761,395
Market Cap $: 837.94 Mil Enterprise Value $: 614.83 Mil
P/E (TTM): 0.00 P/B: 2.96
Earnings Power Value 1.78
Net Current Asset Value 4.55
Tangible Book 6.16
Projected FCF -12.78
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6.4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 16.45
Cash-To-Debt range over the past 10 years
Min: 16.45, Med: 10000, Max: 10000
Current: 16.45
16.45
10000
Debt-to-Equity 0.05
N/A
Debt-to-EBITDA -0.06
Debt-to-EBITDA range over the past 10 years
Min: -0.06, Med: 0, Max: 0
Current: -0.06
-0.06
0
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 9.38
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC -669.94%
WACC 22.65%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -66.63
ROE range over the past 10 years
Min: -89.29, Med: -55.37, Max: -27.36
Current: -66.63
-89.29
-27.36
ROA % -60.11
ROA range over the past 10 years
Min: -75.69, Med: -33.37, Max: -26.55
Current: -60.11
-75.69
-26.55
ROC (Joel Greenblatt) % -393.88
ROC (Joel Greenblatt) range over the past 10 years
Min: -101352.94, Med: -20682, Max: -393.88
Current: -393.88
-101352.94
-393.88
3-Year Total EBITDA Growth Rate -58.70
N/A
3-Year EPS w/o NRI Growth Rate -33.00
N/A

» ATRA's 30-Y Financials

Financials (Next Earnings Date: 2019-08-01)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ATRA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2836
Compare NAS:ZLAB NAS:ORTX NAS:ZGNX NAS:MDGL NAS:BOLD NAS:RUBY NAS:ENTA SZSE:002287 NAS:ARWR NYSE:CBM BOM:539268 NAS:CORT XKRX:006280 NAS:ALEC NAS:XNCR NAS:INVA NAS:IOVA NAS:SGMO OCSE:ALK B NAS:ALLK
Traded in other countries AT2.Germany 0HIY.UK
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening diseases. The company achieves this through two groups of product candidates, such as allogenic or third-party derived antigen-specific T-cells and molecularly targeted biologics.

Ratios

Current vs industry vs history
PB Ratio 2.96
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 8.1
Current: 2.96
0
8.1
EV-to-EBIT -2.38
EV-to-EBIT range over the past 10 years
Min: -14.62, Med: 0, Max: 0
Current: -2.38
-14.62
0
EV-to-EBITDA -2.41
EV-to-EBITDA range over the past 10 years
Min: -14.73, Med: 0, Max: 0
Current: -2.41
-14.73
0
Current Ratio 9.96
Current Ratio range over the past 10 years
Min: 6.23, Med: 21.96, Max: 52.75
Current: 9.96
6.23
52.75
Quick Ratio 9.96
Quick Ratio range over the past 10 years
Min: 6.23, Med: 21.96, Max: 52.75
Current: 9.96
6.23
52.75

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -15.50
3-Year Share Buyback Rate range over the past 10 years
Min: -28.4, Med: -15.75, Max: 0
Current: -15.5
-28.4
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.94
Price-to-Tangible-Book range over the past 10 years
Min: 1.62, Med: 2.9, Max: 8.54
Current: 2.94
1.62
8.54
Earnings Yield (Joel Greenblatt) % -42.70
Earnings Yield (Greenblatt) range over the past 10 years
Min: -168.83, Med: 0, Max: 0
Current: -42.7
-168.83
0

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N